X4 Pharmaceuticals, Inc — Director's Dealing 2020

Jun 11, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2020-06-10

Reporting Person: Skerlj Renato (Chief Scientific Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	30410	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$6.84	2025-12-14	Common Stock (1140.0)		Direct
Stock Option (right to buy)	$13.0	2029-09-26	Common Stock (35000.0)		Direct

Footnotes

F1: Fully vested

F2: 25% of the shares subject to the option shall vest on September 16, 2020, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option on the last day of each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date.